Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6010 + Enlong Subai monoclonal antibody ± 5-FU/capecitabine in first-line advanced/metastatic esophageal squamous cell carcinoma
CTR20254287Phase 3Active
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Nov 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of CPO301 in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by CSPC Megalith Biopharmaceutical Co., Ltd.. Started Nov 2025; status: active.
02
Drugs
CPO301
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on CTR20254287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254287.